ITB Therapy^SM And Stroke

Ed R., stroke survivor. Receiving ITB Therapy since 2004.

Clinical evidence cites 38% of people experience spasticity within one year following a stroke.¹⁹ Managing severe spasticity with Medtronic ITB Therapy^SM (Intrathecal Baclofen Therapy) can result in:

• Efficacy in affected limbs and maintenance of strength on unaffected side^5,6,20
• Significant improvement in walking speed, functional mobility ranges, and spasticity⁵
• Significant improvement in functional motor control, independence, and quality of life²¹
• Improvement in FIM at three and 12 months ²⁰
• Improvement in SIP at three and 12 months²⁰
• Significant decrease in spasticity in upper and lower extremites^5,6,20,21,35

See the Clinical Evidence in Post-Stroke Hypertonia section for more information on these studies and their outcomes.

©Medtronic, Inc. 2008                                                   • Contact Medtronic • Privacy Statement • Terms of Use • Site Map